How to read an NDA refuse-to-file letter

The dread around a drug submission is almost always pointed at the wrong letter. People brace for a Complete Response Letter, issued after months of substantive review, and underestimate the one that can arrive first: a refuse-to-file letter, issued before FDA has reviewed the science at all. The two get confused constantly, and the confusion costs time — the exact thing a refuse-to-file letter threatens most.

What “filing” actually decides

An NDA being “filed” sounds like paperwork, and in the narrowest sense it is — but it’s the gate every substantive review sits behind. Under 21 CFR 314.101(a), FDA has 60 days from receiving an NDA to decide whether the application is complete enough to permit a substantive review. That determination says nothing about whether the drug should eventually be approved. A sponsor can clear it and still receive a Complete Response Letter months later; a sponsor can also never get that far, because the application itself was missing pieces FDA needs before review can start at all. Treating a refuse-to-file letter as a verdict on the science skips a step that hasn’t happened yet.

What actually triggers the letter

FDA’s own guidance on refuse-to-file decisions, Refuse to File: NDA and BLA Submissions to CDER, walks through the deficiencies that support an RTF action under 314.101(d). A few recur more than others: a missing or incomplete application form under (d)(1), an incomplete environmental assessment under (d)(4), and, more broadly, an application FDA considers incomplete on its face under (d)(3). None of these are about whether the clinical data supports the drug’s use — they’re about whether the application, as submitted, contains what FDA needs in order to start reading that data in the first place. A refuse-to-file letter identifies which provision applied and what was missing; it’s a checklist failure, not a scientific one, and the letter itself says exactly where the checklist broke.

The 30-day window, and what it actually buys you

A sponsor who disagrees with an RTF determination can request a written informal conference within 30 days of FDA’s notification, to argue the application should be filed as originally submitted. If the sponsor still wants to proceed after that conference without fixing the underlying gap, the 60-day filing clock restarts — but from the date of the conference request, not from zero and not from the original submission date. That’s the real cost of an RTF: not a rejection, but a reset, and the size of the reset depends on how quickly the deficiency gets addressed rather than argued about.

The device-side analog works the same way in spirit, if not in citation — how to read a PMA refuse-to-file decision covers FDA’s parallel gate for devices. And once an NDA clears filing, the clock that actually matters for planning purposes is the one covered in how to estimate a regulatory submission timeline — filing is the start line, not the finish.